Stroke - Pipeline Review, Q3 2011

Document Sample
Stroke - Pipeline Review, Q3 2011 Powered By Docstoc
					Stroke – Pipeline Review, Q3 2011




                                   Stroke - Pipeline Review, Q3 2011
                                                                                          Reference Code: GMDHC1159IDB

                                                                                          Publication Date: July 2011




Stroke – Pipeline Review, Q3 2011                                                                                       GMDHC1159IDB / Pub July 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                      Page(1)
Stroke – Pipeline Review, Q3 2011



Ta b le o f Co n te n ts
Table of Contents                                                                                                2
List of Tables                                                                                                  11
List of Figures                                                                                                 14
Introduction                                                                                                    15
     Global Markets Direct Report Coverage                                                                      15
Stroke Overview                                                                                                 16
Therapeutics Development                                                                                        17
     An Overview of Pipeline Products for Stroke                                                                17
Stroke Therapeutics under Development by Companies                                                              19
Stroke Therapeutics under Investigation by Universities/Institutes                                              24
Late Stage Products                                                                                             28
     Comparative Analysis                                                                                       28
Mid Clinical Stage Products                                                                                     29
     Comparative Analysis                                                                                       29
Early Clinical Stage Products                                                                                   30
     Comparative Analysis                                                                                       30
Discovery and Pre-Clinical Stage Products                                                                       31
     Comparative Analysis                                                                                       31
Stroke Therapeutics - Products under Development by Companies                                                   32
Stroke Therapeutics - Products under Investigation by Universities/Institutes                                   38
Companies Involved in Stroke Therapeutics Development                                                           42
     Johnson & Johnson                                                                                          42
     NsGene A/S                                                                                                 42
     Sanofi-Aventis                                                                                             43
     AstraZeneca PLC                                                                                            43
     Eli Lilly and Company                                                                                      44
     GlaxoSmithKline plc                                                                                        44
     FASgen, Inc.                                                                                               45
     CardioVascular BioTherapeutics, Inc.                                                                       45
     Aldagen, Inc.                                                                                              46
     Henry Ford Health System                                                                                   46
     Novartis AG                                                                                                47
     Alseres Pharmaceuticals, Inc.                                                                              47
     Acorda Therapeutics, Inc.                                                                                  48
     Glenmark Pharmaceuticals Ltd.                                                                              48
     H Lundbeck A/S                                                                                             49
     Mitsubishi Tanabe Pharma Corporation                                                                       49
     Pfizer Inc.                                                                                                50
     Talecris Biotherapeutics Holdings Corp                                                                     51
     Paratek Pharmaceuticals, Inc.                                                                              52
     Celgene Corporation                                                                                        52
     Bayer AG                                                                                                   53
     Vernalis plc                                                                                               54
     Anavex Life Sciences Corp.                                                                                 55
     Proneuron Biotechnologies, Inc.                                                                            55
     Neuralstem, Inc.                                                                                           56
     Living Cell Technologies Limited                                                                           56


Stroke – Pipeline Review, Q3 2011                                                         GMDHC1159IDB / Pub July 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                        Page(2)
Stroke – Pipeline Review, Q3 2011


     PAION AG                                                                                                   57
     Cortex Pharmaceuticals, Inc.                                                                               57
     Advanced Life Sciences Holdings, Inc.                                                                      58
     BTG International Ltd                                                                                      58
     CytRx Corporation                                                                                          59
     RegeneRx Biopharmaceuticals, Inc.                                                                          59
     POZEN Inc.                                                                                                 60
     ReNeuron Group plc                                                                                         60
     BioInvent International AB                                                                                 61
     SYGNIS Pharma AG                                                                                           61
     Torrent Pharmaceuticals Limited                                                                            62
     Dongwha Pharm Co., Ltd.                                                                                    62
     Hanall Pharmaceutical Co., Ltd.                                                                            63
     Pluristem Therapeutics Inc.                                                                                63
     ThromboGenics NV                                                                                           64
     InDex Pharmaceuticals AB                                                                                   64
     D-Pharm Ltd.                                                                                               65
     StemCells, Inc.                                                                                            65
     KeyNeurotek Pharmaceuticals AG                                                                             66
     BioMAS Ltd.                                                                                                66
     Artielle ImmunoTherapeutics, Inc.                                                                          67
     NormOxys, Inc.                                                                                             67
     Regado Biosciences.                                                                                        68
     PLx Pharma Inc.                                                                                            68
     Ferrer Internacional S.A.                                                                                  69
     Xigen SA                                                                                                   69
     Angion Biomedica Corp.                                                                                     70
     Innogene Kalbiotech Pte Ltd.                                                                               70
     Cornerstone Therapeutics Inc.                                                                              71
     Palkion, Inc.                                                                                              71
     Stemedica Cell Technologies, Inc.                                                                          72
     Taligen Therapeutics Inc.                                                                                  72
     SanBio, Inc.                                                                                               73
     KAI Pharmaceuticals Inc.                                                                                   73
     Lacer, S.A.                                                                                                74
     M's Science Corporation                                                                                    74
     Crimson Pharmaceutical Ltd.                                                                                75
     Thrombotech Technologies, Ltd.                                                                             75
     Gaia BioPharma Limited                                                                                     76
     British Canadian Biosciences Corp.                                                                         76
     ArmaGen Technologies, Inc.                                                                                 77
     Sinapis Pharma, Inc                                                                                        77
     RNL BIO Co., Ltd.                                                                                          78
     InVasc Therapeutics, Inc.                                                                                  78
     PHARMENA SA                                                                                                79
     Artery Therapeutics, Inc.                                                                                  79
     Stempeutics Research Private Limited                                                                       80
Stroke - Therapeutics Assessment                                                                                81




Stroke – Pipeline Review, Q3 2011                                                         GMDHC1159IDB / Pub July 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                        Page(3)
Stroke – Pipeline Review, Q3 2011


     Assessment by Monotherapy Products                                                                         81
     Assessment by Combination Products                                                                         82
     Assessment by Route of Administration                                                                      83
     Assessment by Molecule Type                                                                                86
Late Stage Drug Profiles                                                                                        89
     GSK249320 - Drug Profile                                                                                   89
          Product Description                                                                                   89
          Mechanism of Action                                                                                   89
          R&D Progress                                                                                          89
     Desmoteplase - Drug Profile                                                                                91
          Product Description                                                                                   91
          Mechanism of Action                                                                                   91
          R&D Progress                                                                                          91
     Desmoteplase - Drug Profile                                                                                93
          Product Description                                                                                   93
          Mechanism of Action                                                                                   93
          R&D Progress                                                                                          93
     BI-204 - Drug Profile                                                                                      95
          Product Description                                                                                   95
          Mechanism of Action                                                                                   95
          R&D Progress                                                                                          95
     MCI-186 - Drug Profile                                                                                     96
          Product Description                                                                                   96
          Mechanism of Action                                                                                   96
          R&D Progress                                                                                          96
     Brilinta - Drug Profile                                                                                    97
          Product Description                                                                                   97
          Mechanism of Action                                                                                   97
          R&D Progress                                                                                          97
     PDA001 - Drug Profile                                                                                     100
          Product Description                                                                                  100
          Mechanism of Action                                                                                  100
          R&D Progress                                                                                         100
     Xarelto - Drug Profile                                                                                    101
          Product Description                                                                                  101
          Mechanism of Action                                                                                  101
          R&D Progress                                                                                         101
     Cerestat - Drug Profile                                                                                   103
          Product Description                                                                                  103
          Mechanism of Action                                                                                  103
          R&D Progress                                                                                         103
     Citicoline - Drug Profile                                                                                 104
          Product Description                                                                                  104
          Mechanism of Action                                                                                  104
          R&D Progress                                                                                         104
     Idraparinux - Drug Profile                                                                                105
          Product Description                                                                                  105
          Mechanism of Action                                                                                  105




Stroke – Pipeline Review, Q3 2011                                                         GMDHC1159IDB / Pub July 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                        Page(4)
Stroke – Pipeline Review, Q3 2011


          R&D Progress                                                                                         105
     Multaq - Drug Profile                                                                                     106
          Product Description                                                                                  106
          Mechanism of Action                                                                                  106
          R&D Progress                                                                                         106
     Ocriplasmin - Drug Profile                                                                                107
          Product Description                                                                                  107
          Mechanism of Action                                                                                  107
          R&D Progress                                                                                         107
     DP-b99 - Drug Profile                                                                                     109
          Product Description                                                                                  109
          Mechanism of Action                                                                                  109
          R&D Progress                                                                                         109
     PA32540 - Drug Profile                                                                                    110
          Product Description                                                                                  110
          Mechanism of Action                                                                                  110
          R&D Progress                                                                                         110
     AX200 - Drug Profile                                                                                      111
          Product Description                                                                                  111
          Mechanism of Action                                                                                  111
          R&D Progress                                                                                         111
     GLP-1 Peptide - Drug Profile                                                                              112
          Product Description                                                                                  112
          Mechanism of Action                                                                                  112
          R&D Progress                                                                                         112
     TAL-05-00018 - Drug Profile                                                                               113
          Product Description                                                                                  113
          Mechanism of Action                                                                                  113
          R&D Progress                                                                                         113
     Radicut - Drug Profile                                                                                    114
          Product Description                                                                                  114
          Mechanism of Action                                                                                  114
          R&D Progress  
				
DOCUMENT INFO
Description: Stroke - Pipeline Review, Q3 2011 Summary Global Markets Direct’s, 'Stroke - Pipeline Review, Q3 2011', provides an overview of the Stroke therapeutic pipeline. This report provides information on the therapeutic development for Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Stroke. 'Stroke - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Stroke. - A review of the Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Stroke pipeline on the basis of therapeutic class, route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Stroke. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effec
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries